Fibromodulin Ablation Exacerbates the Severity of Acute Colitis

Marianna Halasi1, Mor Grinstein2, Avner Adini3, Irit Adini1

1Department of Surgery, Center for Engineering in Medicine & Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 2Department of Medicine, Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 3Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA

Correspondence: Irit Adini, Emailiadini@mgh.harvard.edu

Introduction: Epidemiological studies have associated pigment production with protection against certain human diseases. In contrast to African Americans, European descendants are more likely to suffer from angiogenesis-dependent and inflammatory diseases, such as wet age-related macular degeneration (ARMD) and ulcerative colitis (UC), respectively.

Methods: In a mouse model of dextran sulfate sodium (DSS)-induced acute colitis, the effect of fibromodulin (FMOD) depletion was examined on colitis severity.

Results: In this study, albino mice that produce high levels of FMOD developed less severe acute colitis compared with mice lacking in FMOD as assessed by clinical symptoms and histopathological changes. FMOD depletion affected the expression of tight junction proteins, contributing to the destruction of the epithelial barrier. Furthermore, this study revealed a stronger inflammatory response after DSS treatment in the absence of FMOD, where FMOD depletion led to an increase in activated T cells, plasmacytoid dendritic cells (pDCs), and type I interferon (IFN) production.

Discussion: These findings point to FMOD as a potential biomarker of disease severity in UC among light-skinned individuals of European descent.

Keywords: inflammatory bowel disease, ulcerative colitis, fibromodulin, tight junction, dendritic cells
that FMOD up-regulates transforming growth factor beta-1 (TGF-β1) secretion. TGF-β1 appears to enhance intestinal epithelial barrier function by inducing the production of TJ proteins, such as claudin-1, occludin, and ZO-1. Furthermore, TGF-β1 is well known for its role in maintaining DCs in an immature state. During activation and migration of immature DCs to inflammatory sites, the DCs interact directly with ECM microenvironment proteins, such as FMOD, resulting in DC differentiation and maturation.

To advance our understanding of the pathogenesis of UC, we investigated the role of FMOD in a dextran sulfate sodium (DSS)-induced murine model of acute colitis, as well as in biopsy samples from healthy and diseased individuals with IBD.

Methods

Mice

Mutant B6 (Cg)-Tyrc<sup>−2/J</sup> (FMOD+/+) 8–10-week-old male mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The mutant B6 (Cg)-Tyrc<sup>−2/J</sup> transgenic FMOD knockout (FMOD−/−) animals were established previously as described. The knockout animals were bred and maintained in pathogen-free conditions in the animal facility of Massachusetts General Hospital, Boston, MA, USA. All animals were housed on 12 hr light–dark cycles under controlled temperatures, and they had free access to standard diet and water. All animal experiments were approved by and were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee at Massachusetts General Hospital.

Induction of Experimental DSS Colitis

Acute colitis was induced in age-, and gender-matched, parental FMOD+/+ and FMOD−/− mice by the administration of 3% DSS (molecular weight 36,000–50,000; MP Biomedicals, Solon, OH, USA) ad libitum in autoclaved drinking water for 7 days. Body weight, stool consistency and bleeding were recorded daily to monitor colitis development. On day 7 after the start of DSS treatment, the animals were sacrificed, the gross pictures of the colon from cecum to rectum were taken, colon length was measured, and the colon tissue samples were processed for further downstream analysis.

Human Samples

Colon biopsy sections of healthy individuals and patients diagnosed with ulcerative colitis were purchased from UMass Chan Medical School Tissue Bank Facility (Worcester, MA, USA).

Scoring of Bleeding

Bleeding score criteria follows as: 0 = no blood; 1 = small blood spot around anus; 2 = visible rectal bleeding; 3 = dried, chunks of blood on fur around anus.

Scoring of Disease Activity Index (DAI)

DAI was calculated by the addition of the average weight loss score, the average stool consistency score and the average bleeding score and then divided by 3. Weight loss score criteria follows as: 0 = no weight loss; 1 = 1–5% weight loss; 2 = 6–10% weight loss; 3 = 11–20% weight loss. Stool consistency score follows as: 0 = normal; 1 = loose stool; 2 = elongated loose stool; 3 = diarrhea.

Scoring of H&E Sections

On the day of termination, the colon was removed, flushed with ice cold phosphate buffered saline (PBS) to remove feces and blood, cut longitudinally and prepared as a Swiss roll for fixation in 4% paraformaldehyde (PF). Paraffin embedded sections were stained with Hematoxylin and Eosin (H&E) and histological scoring was performed in a blinded fashion independently by two pathologists. The histological sections were examined for the integrity of tissue architecture (0–4), ulceration (0–4), and submucosal edema (0–4).
**Total RNA Extraction and Quantitative Real-Time PCR (qRT-PCR)**

Colon tissue samples were processed by the IBI Isolate reagent (IBI Scientific, Dubuque, IA, USA) for total RNA extraction. The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA) was used to synthesize complementary DNA (cDNA). Quantitative real-time PCR reactions were run on the LightCycler 480 instrument (Roche, Indianapolis, IN, USA) using the PrimeTime Gene Expression Master Mix (IDT DNA, Coralville, IA, USA) and the following mouse primers: Claudin1-S, 5’-ACA GCA TGG TAT GGA AAC AGA-3’, Claudin1-AS, 5’-AGG AGC AGG AAA GTA GGA CA-3; IFNα/β-S, 5’-TTC CTC AGC CAA GTT GGT T-3’, IFNα/β-AS, 5’-GTG CAT GGT CCT AGT CCA G-3’; Occludin-S, 5’-CAC TAT GAA ACA GAC TAC ACG ACA-3’, Occludin-AS, 5’-GTG CAT GGT CCT AGT CCA G-3’; ZO-1-S, 5’-AAT GAA TAA TAT CAG CAC CAT GCC-3’, ZO-1-AS, 5’-GCC ACT ACA GGA TGA CCA GCC TCC-3’; 18S-S, 5’-GAG ACT CTG GCA TGC TAA GTA G-3’, 18S-AS, 5’-GGA CAT CTA AGG GCA TCA CAG-3’; GAPDH-S, 5’-AAT GGT GAA GGT CGG TGT G-3’, GAPDH-AS, 5’-GTG GAG TCA TAC TGG AAC ATG TAG-3’.

**Cell Isolation and Flow Cytometry**

Mesenteric lymph nodes (mLN) of DSS treated animals were isolated, passed through a 100-µm cell strainer and red blood cells were lysed with the RBC lysis buffer (Biolegend, San Diego, CA, USA). To differentiate between live and dead cells, cells were stained for 15 min at room temperature with the Zombie UV Fixable Viability Kit (Biolegend, San Diego, CA, USA) as per the company's recommendation. Cell surface staining was performed for 30 min at 4°C with fluorochrome-conjugated monoclonal antibodies to mouse antigens purchased from Biolegend (San Diego, CA, USA): CD45 (30-F11), CD11c (N418), PDCA-1 (927), CD3 (17A2), CD4 (GK1.5), CD25 (PC61). Following staining cells were washed and fixed in 4% PF.

For intracellular staining, cells first were stained for cell surface markers, washed, then fixed, permeabilized and stained for intracellular transcription factor FoxP3 (MF-14; Biolegend, San Diego, CA, USA) for 30 min at RT. Samples were analyzed by the FACSARia cell sorter (BD Biosciences, Franklin Lakes, NJ, USA), and the acquired data were analyzed using FlowJo software (version 10.6.1) (Ashland, OR, USA).

**Microscopy and Immunofluorescence Staining**

Brightfield images of H&E-stained sections were captured by Nikon Eclipse Ti2 microscope (Melville, NY, USA). For immunofluorescence staining, paraffin-embedded colon sections were rehydrated by incubating in a series of xylene, ethanol (100%, 95%, 70% and 50%) and phosphate-buffered saline (PBS) solutions. After blocking, primary antibodies of CD45 (Biolegend, San Diego, CA, USA), claudin-1 (BiCell Scientific, Maryland Heights, MO, USA), FMOD (Abcam, Cambridge, MA, USA) occludin (BiCell Scientific, Maryland Heights, MO, USA) or ZO-1 (BiCell Scientific, Maryland Heights, MO, USA) were applied for overnight incubation. As for secondary antibodies, Alexa Fluor 594 (Invitrogen, Waltham, MA, USA) and Alexa Fluor 647 (Invitrogen, Waltham, MA, USA) were utilized. To visualize nuclei, slides were mounted with VECTASHIELD Antifade mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Fluorescence imaging was performed with Nikon Eclipse Ti2 microscope (Melville, NY, USA) or Leica SP8 X confocal microscope (Deerfield, IL, USA). Acquired images were analyzed using the NIS Elements software (Nikon, Melville, NY, USA) or the LASX life science software (Leica, Deerfield, IL, USA). Mean Fluorescence Intensity (MFI) was calculated by ImageJ 8.

**Statistical Analysis**

Statistical analysis was performed with GraphPad Prism software (San Diego, CA, USA) as described in the figure legends. *P* values of <0.05 were considered to be statistically significant.

**Results**

**FMOD Expression is Affected by UC in Human Subjects and Mice**

The expression of FMOD was assessed by immunostaining the colon biopsy samples from healthy control individuals and patients diagnosed with UC. As shown in Figure 1A (left panel), in healthy individuals, FMOD was mainly detected...
in the brush border on the luminal cell surface of the colon. In contrast, a significant increase in FMOD expression was observed in the crypts of colon biopsy samples from UC patients (Figure 1A, right panel).

Since DSS-induced colitis is a well-established and commonly used animal model\(^{19,20}\) that mirrors key aspects of human IBD, especially UC, FMOD level and localization was evaluated in animals with DSS-induced colitis. FMOD expression demonstrated the same distribution observed in the human samples (Figure 1B).

**Figure 1** FMOD is upregulated and re-localized in colitis. (A) Colon biopsy samples from healthy individuals and patients diagnosed with UC were stained with H&E or subjected to immunostaining for FMOD. Representative images were captured at x20 magnification. (B) FMOD+/- mice were given 3% DSS in drinking water for 7 days. Representative samples were H&E stained or immunostained for FMOD. Images were obtained at x20 magnification.
Depletion of FMOD Aggravated the DSS-Induced Clinical Symptoms of Colitis

To determine the role of FMOD in the development of acute colitis, age-matched transgenic FMOD knockout (FMOD-/-) male mice, along with FMOD+/+ animals, were exposed to 3% DSS for 7 days as described in Materials and Methods. The clinical signs of DSS-induced acute colitis, which include changes in body weight, bleeding, and fecal consistency, were recorded daily to monitor onset and progression of disease. Both FMOD+/+ and FMOD-/- DSS-treated experimental animals showed similar signs of acute colitis, including body weight loss (Figure 2A) and shortening of the colon (Figure 2B and C). However, DSS-treated FMOD-/- mice began losing weight 3 days after DSS was administered, while

![Figure 2](https://doi.org/10.2147/JIR.S366290)
weight loss in FMOD+/+ animals began 5 days after DSS was administered. During the remainder of the DSS treatment, all of the treated animals showed substantial weight loss, amounting to 8.37% and 10% of their original weight in FMOD+/+ and FMOD-/- animals, respectively (Figure 2A).

One of the hallmarks of chemically induced colitis is colon shortening. As with the weight loss findings, colon shortening was similar between the treated groups on the day of necroscopy (19.71% in FMOD+/+ and 20.29% in FMOD-/-) but was significantly shorter compared to the respective untreated controls (Figure 2B and C). Furthermore, both DSS-treated groups were visually checked for signs of rectal bleeding. Like weight loss, bleeding onset occurred earlier in the DSS-treated FMOD-/- animals, which started bleeding on day 3, compared to day 4 in the FMOD+/+ mice (Figure 2D). Nevertheless, rectal bleeding remained more prominent in the FMOD-/- animals over the period of DSS treatment. The disease activity index (DAI) score (the sum of the average weight loss score, the average stool consistency score, and the average bleeding score divided by 3), as shown in Figure 2E, indicated the FMOD-/- animals showed signs of colitis earlier and developed more severe disease compared with FMOD+/+ mice.

Together, these results demonstrated that the severity and onset of clinical symptoms of colitis, including weight loss, rectal bleeding, and diarrhea, were exacerbated in the FMOD knockout animals.

**FMOD-Ablated Mice Exhibited Severe Pathological Changes of the Colon After DSS Treatment**

In addition to the phenotypical signs of colitis, histopathological changes in the colon were examined to further evaluate the possible role of FMOD in DSS-induced acute colitis. For histological H&E staining, the flushed and longitudinally cut colons were prepared using Swiss roll technique to permit a fuller assessment of the colonic pathology compared to the limited scope of transverse or longitudinal sections. Histological observations were carried out to assess the structural integrity of the intestinal epithelium (Figure 3A). Colon sections from animals in both groups exhibited a fully intact epithelium with well-defined crypts, no edema, no leukocyte infiltration in the mucosa or sub-mucosa, and no ulceration or erosions (Figure 3A). In contrast, the colon sections of DSS-treated animals showed different degrees of gut barrier compromise in the FMOD+/+ and FMOD-/- groups. Typical histological changes, including the presence of mononuclear inflammatory cells, disappearance of goblet cells, degradation of the epithelium, ulceration, edema, and leukocyte infiltration in the mucosa and sub-mucosa, were noted at different levels among the DSS-treated groups (Figure 3A).

In addition, the colon samples were scored blindly for the following criteria: destruction of architecture (0–4), ulceration (0–4), and edema (0–4) (Figure 3B). The detailed quantitative histological analysis revealed more advanced disease in the DSS-treated FMOD-/- mice with an overall histological score average of 2.9 compared to the FMOD+/+ mice, which had an overall histological score average of 2 (Figure 3B).

Taken together, these results suggested that although FMOD+/+ and FMOD-/- mice showed similar physical characteristics of acute colitis, they demonstrated marked differences in colonic histopathology after DSS treatment, in which the FMOD-/- animals showed higher susceptibility to DSS and developed more severe colitis. The histological analysis underscores FMOD’s role in moderating the damage inflicted by DSS on the epithelium, since knockout of FMOD resulted in substantial further damage.

**FMOD Ablation Facilitated Epithelial Barrier Erosion**

By its nature, DSS has the capacity to compromise the structural integrity of the epithelial cell barrier, possibly due to its interference with TJ proteins. To evaluate the effects of FMOD on the composition and expression of TJ proteins in DSS-induced colitis, colonic samples of untreated and DSS-treated groups were analyzed by immunofluorescence and qRT-PCR.

Our analysis focused on intracellular protein ZO-1 and transmembrane proteins occludin and claudin-1 on account of their well-established involvement in the impairment of intestinal barrier function in IBD disease models. ZO-1 protein expression was reduced, while claudin-1 expression was substantially upregulated (Figure 4A) and occludin expression did not show a significant change (data not shown) in the DSS-treated colon sections of FMOD-/- mice compared to treated FMOD+/+ mice. Furthermore, quantification of fluorescence intensity by ImageJ showed a 40%
decrease in ZO-1 protein expression and a 1.6-fold increase of claudin-1 expression in DSS-treated FMOD-/- mice compared to treated FMOD+/+ mice (Figure 4B). To account for changes in protein expression levels, we also validated these findings at the mRNA level. The results showed that the mRNA level of ZO-1 was significantly reduced, claudin-1 mRNA was substantially upregulated, while occludin mRNA expression showed no statistically significant change in the DSS-treated FMOD-/- mice (Figure 4C).

Poritz et al.21 found that occludin levels decrease and claudin-1 levels increase in the colon of human subjects with UC, resulting in a higher claudin-1:occludin (C:O) ratio compared to healthy colon. Using the C:O ratio calculated from the respective mRNA expression levels, we observed a 3-fold increase in disease severity in the absence of FMOD after DSS treatment (Figure 4D).
Leukocyte infiltration has been associated with the pathogenesis of human IBD. It has also been implicated in the acute phase of DSS-induced colitis.

The presence of leukocytes in the colonic tissue was assessed by immunostaining for CD45 on colon sections from DSS-treated mice. Higher expression of CD45 (Figure 5A) was observed in DSS-treated FMOD-/- animals, suggesting inflammation becomes more robust in the absence of FMOD.

Colonic inflammation was further examined by assessing cytokine production in the colonic tissue and the immune response in mesenteric lymph nodes (mLNs), which are known to drain the colonic tissue. First, the production of

**Figure 4** Knockout of FMOD amplifies the changes in expression of TJ proteins following DSS treatment. (A) Paraffin-embedded sections of DSS-treated colon Swiss rolls were stained with anti-mouse ZO-1 or claudin-1. Images were captured at x20 magnifications. (B) The graph shows the quantification of mean fluorescence intensity (MFI). (C) The transcriptional expression of TJ proteins ZO-1, claudin-1, and occludin was measured by qRT-PCR in the colon of untreated and DSS-treated FMOD+/+ and FMOD-/- mice. The graphs show quantification as fold of mRNA expression levels compared to untreated FMOD+/+ mice (n=3), mean ± SEM 3 (FMOD+/+) or 4 (FMOD-/-) control and 8 (FMOD+/+) or 10 (FMOD-/-) treated mice. (D) The claudin-1: occludin ratio was calculated using the respective mRNA expression levels. Statistical analysis was performed by unpaired, two-tailed t test with Welch’s correction: *P < 0.05, **P < 0.01.

**FMOD Alleviated DSS-Induced Colonic Inflammation**

Leukocyte infiltration has been associated with the pathogenesis of human IBD. It has also been implicated in the acute phase of DSS-induced colitis.24–26 The presence of leukocytes in the colonic tissue was assessed by immunostaining for CD45 on colon sections from DSS-treated mice. Higher expression of CD45 (Figure 5A) was observed in DSS-treated FMOD-/- animals, suggesting inflammation becomes more robust in the absence of FMOD.
inflammatory mediators was measured in colon tissue samples by qRT-PCR. Markedly higher mRNA expression of immunomodulatory cytokine interferon α/β (IFN α/β) was observed in the DSS-treated FMOD-/- animals, underscoring the development of a potentially more robust inflammatory response (Figure 5B).

To characterize the recruited and activated immune cell populations in systemic organs following DSS exposure, mLNs and spleens were harvested and analyzed by flow cytometry. A decrease in the splenic dendritic cell (DC) and T cell populations in both DSS-treated groups was detected (data not shown). Significantly more plasmacytoid dendritic cells (pDCs) with increased MHC II (major histocompatibility complex II) maturation markers on their surface were observed in the mLNs of treated FMOD-/- animals (Figure 5C). Analysis of T cells revealed significantly more activated T cells in the DSS-treated FMOD-/- group, while increased mobilization of FoxP3+ T reg cells was observed in the FMOD+/+ DSS-treated mice (Figure 5D), corroborating the presence of a stronger inflammatory response in the background of FMOD KO after DSS administration.

These results suggest that in the absence of FMOD, acute inflammation, represented by activated pDCs and reduced numbers of T regulatory cells, is significantly increased.

Figure 5 FMOD moderates DSS-induced colonic inflammation. (A) Paraffin-embedded sections of the DSS-treated colon Swiss rolls were stained with anti-mouse CD45. Images were captured at x20 magnifications. (B) The transcriptional expression of IFNα/β was measured by qRT-PCR in the colon. The graph shows quantification as fold of mRNA expression levels compared to untreated FMOD+/+ mice (n=3), mean ± SEM 3 (FMOD+/+) or 4 (FMOD-/-) control and 8 (FMOD+/+) or 10 (FMOD-/-) treated mice. *P<0.05 by unpaired, two-tailed t test with Welch’s correction. (C) The mesenteric lymph nodes (mLNs) of DSS-treated FMOD+/+ (n=5) and FMOD-/- (n=5) mice were analyzed by flow cytometry for the frequency (left panel) and the maturity (right panel) of pDCs. Data are shown as a dot plot (frequency) or a density plot (maturity), and numbers represent the percentage of CD11c⁺PDCA-1⁺ pDCs or CD11c⁺PDCA-1⁺MHC II⁺ pDCs among the live CD45⁺ leukocytes, respectively. (D) Cells from the mLNs of treated FMOD+/+ and FMOD-/- mice were stained for the expression of CD25 and FoxP3 and analyzed by flow cytometry. Dot plots show CD25 and CD4 staining pre-gated on live CD45⁺CD3⁺ cells. The histogram represents FoxP3 staining pre-gated on live CD45⁺CD3⁺CD4⁺CD25⁺ cells.

inflammatory mediators was measured in colon tissue samples by qRT-PCR. Markedly higher mRNA expression of immunomodulatory cytokine interferon α/β (IFN α/β) was observed in the DSS-treated FMOD-/- animals, underscoring the development of a potentially more robust inflammatory response (Figure 5B). To characterize the recruited and activated immune cell populations in systemic organs following DSS exposure, mLNs and spleens were harvested and analyzed by flow cytometry. A decrease in the splenic dendritic cell (DC) and T cell populations in both DSS-treated groups was detected (data not shown). Significantly more plasmacytoid dendritic cells (pDCs) with increased MHC II (major histocompatibility complex II) maturation markers on their surface were observed in the mLNs of treated FMOD-/- animals (Figure 5C). Analysis of T cells revealed significantly more activated T cells in the DSS-treated FMOD-/- group, while increased mobilization of FoxP3+ T reg cells was observed in the FMOD+/+ DSS-treated mice (Figure 5D), corroborating the presence of a stronger inflammatory response in the background of FMOD KO after DSS administration.

These results suggest that in the absence of FMOD, acute inflammation, represented by activated pDCs and reduced numbers of T regulatory cells, is significantly increased.
Discussion
Ulcerative colitis is an idiopathic IBD limited to the colon. It is multifactorial in nature, characterized by dysregulation of the immune system, epithelial barrier defects, and changes in the intestinal microbiota. Based on our earlier findings, we hypothesize that FMOD, a prominent ECM protein, plays a role in inflammation and in the maintenance of the epithelial barrier. This study investigates the potential role of FMOD in the pathogenesis of UC utilizing the widely used DSS-induced acute colitis mouse model.

FMOD, a cytosolic protein with a known secretory sequence but no transmembrane domain, is characterized as a class II member of the small leucine-rich proteoglycan family. It was first described in human articular cartilage. Although it is ubiquitously expressed in all tissues among vertebrates, its expression is most abundant in the extracellular matrix (ECM) of the connective tissues, where it plays a key role in the organization of collagen fibrils. In recent years, additional tissue-specific activities have been reported, such as its role in muscle development, cell reprogramming, angiogenesis, and regulation of TGF-β1 secretion. FMOD has also been associated with inflammatory diseases of the joint and anti-inflammatory responses in wound healing. To date, the role of FMOD in inflammatory and autoimmune diseases has been modestly explored. Increased expression of FMOD has been observed in patients with fibrotic kidney disease, heart failure, and atherosclerosis.

Through our experiments, we observed upregulated FMOD expression in both IBD patients and animals with DSS-induced acute colitis (Figure 1). This observation may not be too surprising, since colitis causes oxidative stress, which is well known to stimulate the expression of FMOD. Interestingly, however, deletion of FMOD in a transgenic acute colitis mouse model did not alleviate disease burden. Rather, it intensified the onset and severity of the clinical colitis symptoms as measured by weight loss, rectal bleeding, and DAI score (Figure 2). In addition, histopathological examination of full-length colon sections underscored the development of more severe colitis in the absence of FMOD (Figure 3).

The epithelial barrier physically separates the host immune cells in the intestinal mucosa from the luminal microbiota. Damage to the integrity of the colonic epithelia increases mucosal permeability due to the dysregulation of TJ proteins. Although, epithelial barrier erosion is a key feature of clinical IBD, it is still debated whether such dysfunction is a manifestation or a cause of UC. Loss and redistribution of tight junction proteins are commonly reported in acute DSS colitis. In agreement with these findings, marked differences in mRNA and protein expression of TJ proteins, ZO-1 and claudin-1, were observed between the DSS-treated groups (Figure 4), showing more robust changes in the absence of FMOD.

Further investigation into the effect of FMOD depletion on colitis revealed the presence of a stronger inflammatory immune response in DSS-treated FMOD-/- mice (Figure 5). Studies have shown that FMOD plays an important role in inflammatory responses through activating the classical and alternative complement pathways by directly binding to C1q and C3b. The activated complement system contributes to the adaptive and cellular immune responses by interacting with toll-like receptors (TLRs), antigen-presenting cells, and immune cells such as polymorphonuclear leukocytes, DCs, B cells, as well as T lymphocytes. Interestingly, the deposition of C1q can also inhibit molecular processes required for DC differentiation and IFN-α production by pDCs. Our results align with these previously described findings. Specifically, the presence of FMOD in FMOD+/+ animals, probably via complement activation, induced a more protective immune response as evidenced by the higher number of FoxP3+ T reg cells. Likewise, the absence of FMOD in FMOD-/- animals was associated with increased production of type I IFN, higher numbers of pDCs, and activated T cells indicating a stronger inflammatory response (Figure 5).

Here, we provide insight into the connection between FMOD and the increased susceptibility to colitis by employing genetic and biochemical approaches. In the acute phase of DSS-induced colitis, the presence of FMOD alleviates disease symptoms by maintaining the integrity of the epithelial barrier, reducing pDC activation, and inducing regulatory T cell responses. Future studies are warranted to examine the potential utility of tissue FMOD as a biomarker to gauge the severity of UC among light-skinned individuals of European descent.

Acknowledgment
The authors thank Professors Rivka Dresner-Pollak, MD, Martin L. Yarmush, MD, PhD and Yuval Tal, MD, PhD for fruitful discussions. This study was supported in part by a grant from NIH (RO1EY024046).
Disclosure

The authors report no conflicts of interest in this work.

References

1. Zhou I, Lai W, Yang W, et al. BLT1 in dendritic cells promotes Th1/Th17 differentiation and its deficiency ameliorates TNBS-induced colitis. *Cell Mol Immunol.* 2018;15:1047–1056. doi:10.1038/s41423-018-0030-2

2. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. *Lancet.* 2012;380:1606–1619. doi:10.1016/S0140-6736(12)60150-0

3. Zou J, Liu C, Jiang S, Qian D, Duan J. Cross talk between gut microbiota and intestinal mucosal immunity in the development of ulcerative colitis. *Infect Immun.* 2021;89:e0001421. doi:10.1128/IAI.00014-21

4. Torres J, Mehndir S, Colombel JF, Peyrin-Biroulet L, Crohn’s disease. *Lancet.* 2017;389:1741–1755. doi:10.1016/S0140-6736(16)31711-1

5. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterol.* 2014;14:189. doi:10.1186/s12867-014-0189-7

6. Paris L, Tonutti L, Vannini C, Bazzoni G. Structural organization of the tight junctions. *Biochim Biophys Acta.* 2008;1778:646–659. doi:10.1016/j.bbamem.2007.08.004

7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature.* 1998;392:245–252. doi:10.1038/32588

8. Rescigno M, Granucci F, Citterio S, Foti M, Ricciardi-Castagnoli P. Coordinated events during bacteria-induced DC maturation. *Immunol Today.* 1999;20:200–203. doi:10.1016/S0167-5699(98)01427-3

9. Huang F, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. *J Exp Med.* 2000;191:435–444. doi:10.1084/jem.191.3.435

10. Sjoberg A, Oommen P, Morgelin M, Heinegard D, Blom AM. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. *J Biol Chem.* 2005;280:32301–32308. doi:10.1074/jbc.M504828200

11. Merle NS, Noe R, Hallwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. *Front Immunol.* 2015;6:257. doi:10.3389/fimmu.2015.00257

12. Adini I, Ghosh K, Adini A, et al. Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment. *J Clin Invest.* 2014;124:425–436. doi:10.1172/JCI69404

13. Adini I, Adini A, Bazinet L, Watnick RS, Bielenberg DR, D’Amato RJ. Melanocyte pigmentation inversely correlates with MCP-1 production and angiogenesis-inducing potential. *FASEB J.* 2015;29:662–670. doi:10.1096/fj.14-255398

14. Kontos CD. More than skin deep: connecting melanocyte pigmentation and angiogenic diseases. *J Clin Invest.* 2014;124:76–79. doi:10.1172/JCI73559

15. Howe KL, Reardon C, Wang A, Nazli A, McKay DM. Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability. *J Immunol.* 2005;167:1587–1597. doi:10.4049/jimmunol.1000981

16. Kel JM, Girard-Madoux MJ, Reizis B, Clausen BE. TGF-beta is required to maintain the pool of immature Langerhans cells in the epidermis. *J Immunol.* 2010;185:3248–3255. doi:10.4049/jimmunol.1000981

17. Kel JM, Girard-Madoux MJ, Reizis B, Clausen BE. TGF-beta is required to maintain the pool of immature Langerhans cells in the epidermis. *J Immunol.* 2010;185:3248–3255. doi:10.4049/jimmunol.1000981

18. Halberg J, Steinman RM. Dendritic cells and the control of immunity. *Nature.* 1998;392:245–252. doi:10.1038/32588

19. Kontos CD. More than skin deep: connecting melanocyte pigmentation and angiogenic diseases. *J Clin Invest.* 2014;124:76–79. doi:10.1172/JCI73559

20. Howe KL, Reardon C, Wang A, Nazli A, McKay DM. Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability. *J Immunol.* 2005;167:1587–1597. doi:10.4049/jimmunol.1000981

21. Kel JM, Girard-Madoux MJ, Reizis B, Clausen BE. TGF-beta is required to maintain the pool of immature Langerhans cells in the epidermis. *J Immunol.* 2010;185:3248–3255. doi:10.4049/jimmunol.1000981

22. Brand U, Bellinghausen I, Enk AH, et al. Influence of extracellular matrix proteins on the development of cultured human dendritic cells. *J Exp Med.* 1998;185:3248–3255. doi:10.1083/jem.185.3.3248–3255.
31. Lee YH, Schiemann WP. Fibromodulin suppresses nuclear factor-kappaB activity by inducing the delayed degradation of IKBA via a JNK-dependent pathway coupled to fibroblast apoptosis. *J Biol Chem*. 2011;286:6414–6422. doi:10.1074/jbc.M110.168682
32. Lee EJ, Jan AT, Baig MH, et al. Fibromodulin: a master regulator of myostatin controlling progression of satellite cells through a myogenic program. *FASEB J*. 2016;30:2708–2719. doi:10.1096/fj.201500133R
33. Zheng Z, Jian J, Zhang X, et al. Reprogramming of human fibroblasts into multipotent cells with a single ECM proteoglycan, fibromodulin. *Biomaterials*. 2012;33:5821–5831. doi:10.1016/j.biomaterials.2012.04.049
34. Zheng Z, Jian J, Velasco O, et al. Fibromodulin enhances angiogenesis during cutaneous wound healing. *Plast Reconstr Surg Glob Open*. 2014;2:e275. doi:10.1097/GOX.0000000000000243
35. Jan AT, Lee EJ, Choi I. Fibromodulin: a regulatory molecule maintaining cellular architecture for normal cellular function. *Int J Biochem Cell Biol*. 2016;80:66–70. doi:10.1016/j.biocel.2016.09.023
36. Zeng-Brouwers J, Pandey S, Trebicka J, Wygrecka M, Schaefer L. Communications via the small leucine-rich proteoglycans: molecular specificity in inflammation and autoimmune diseases. *J Histochem Cytochem*. 2020;68:887–906. doi:10.1369/0022155420930303
37. Schaefer L, Gröne H-J, Raslik I, et al. Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. *Kidney Int*. 2000;58:1557–1568. doi:10.1046/j.1523-1755.2000.00317.x
38. Mormone E, Lu Y, Ge X, Fiel MI, Nieto N. Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. *Gastroenterology*. 2012;142:612.e615–621.e615. doi:10.1053/j.gastro.2011.11.029
39. Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. *J Biomech Biotechnol*. 2012;2012:718617. doi:10.1155/2012/718617
40. Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. *Cell Mol Gastroenterol Hepatol*. 2017;4:33–46. doi:10.1016/j.jcmgh.2017.03.007
41. Lee JY, Wasinger V, Yau Y, et al. Molecular pathophysiology of epithelial barrier dysfunction in inflammatory bowel diseases. *Proteomes*. 2018;6:0:17. doi:10.3390/proteomes6020017
42. Heeger PS, Kemper C. Novel roles of complement in T effector cell regulation. *Immunobiology*. 2012;217:216–224. doi:10.1016/j.imbio.2011.06.004
43. Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. *Proc Natl Acad Sci USA*. 2012;109:E3160–E3167. doi:10.1073/pnas.1212753109
44. Lood C, Gullstrand B, Truedsson L, et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. *Arthritis Rheum*. 2009;60:3081–3090. doi:10.1002/art.24852
45. Bencze D, Fekete T, Pazmandi K. Type I interferon production of plasmacytoid dendritic cells under control. *Int J Mol Sci*. 2021;22:4190. doi:10.3390/ijms22084190